Index Fund Advisors Inc. Makes New Investment in Johnson & Johnson $JNJ

Index Fund Advisors Inc. purchased a new stake in Johnson & Johnson (NYSE:JNJ) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 31,176 shares of the company’s stock, valued at approximately $5,781,000. Johnson & Johnson accounts for about 0.3% of Index Fund Advisors Inc.’s holdings, making the stock its 24th largest position.

Other institutional investors have also added to or reduced their stakes in the company. Clayton Financial Group LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at $28,000. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $27,000. Semmax Financial Advisors Inc. grew its stake in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after purchasing an additional 72 shares during the period. GFG Capital LLC bought a new stake in Johnson & Johnson in the second quarter worth approximately $35,000. Finally, Signature Resources Capital Management LLC lifted its stake in Johnson & Johnson by 262.9% in the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after buying an additional 184 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the subject of several research analyst reports. Citigroup lifted their price objective on shares of Johnson & Johnson from $215.00 to $232.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. HSBC restated a “buy” rating and issued a $240.00 target price on shares of Johnson & Johnson in a research note on Wednesday, December 10th. The Goldman Sachs Group upped their price target on Johnson & Johnson from $213.00 to $240.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Finally, UBS Group restated a “buy” rating on shares of Johnson & Johnson in a report on Monday. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $213.33.

Johnson & Johnson Trading Down 0.6%

NYSE JNJ opened at $204.47 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The business has a fifty day simple moving average of $202.87 and a 200 day simple moving average of $184.52. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $215.18. The firm has a market capitalization of $492.62 billion, a P/E ratio of 19.74, a PEG ratio of 2.11 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Barclays raised its JNJ price target on strength in key drugs, signaling analyst confidence in the company’s mid-term revenue drivers. Barclays Raises Johnson & Johnson (JNJ) Target on Strength in Key Drugs
• Positive Sentiment: Deal with the Trump administration gives JNJ tariff exemptions and accelerates a reported ~$55 billion plan to expand U.S. manufacturing — this reduces tariff risk, improves supply-chain resilience and could support margins over time. J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve
• Positive Sentiment: Clinical and product-development catalysts: mid-stage success for nipocalimab in SLE and J&J MedTech’s Ottava surgical robot submission to the FDA could drive future revenue and sentiment if approvals/commercialization progress. J&J succeeds in mid-stage trial for SLE therapy Johnson & Johnson MedTech submits Ottava surgical robot to FDA
• Neutral Sentiment: Sector tailwind: healthcare stocks have been rallying and JNJ sits in many health-care ETFs, which can provide passive-buying support independent of company-specific news. This ETF Is Proof That the Healthcare Rebound Is Real
• Neutral Sentiment: Partnerships and collaborations (e.g., Lexeo on cardiac gene therapy) expand J&J’s pipeline exposure but are longer-term and incremental to near-term earnings. Lexeo Therapeutics Announces Research Collaboration with Johnson & Johnson
• Negative Sentiment: JNJ agreed to cut U.S. drug prices as part of the government deal — that creates near- and medium-term revenue/price pressure for affected medicines and is a headline risk for investors focused on margins. Johnson & Johnson reaches deal with US government to lower drug prices
• Negative Sentiment: Zacks trimmed several near-term EPS estimates (Q1–Q4 and FY2027) marginally — this reflects some analyst caution after the pricing agreement and contributes to downward pressure on the stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.